Description: Cancer is one of the leading causes of mortality amongst world’s population, in which prostate cancer (PCa) is one of the most encountered malignancies among men. Several molecular mechanisms are involved in prostate cancer development and progression. These include common survival factors in prostate cancer (IGF-1), growth factors (TGF-α, EGF), Wnt, Hedgehog, NF-κB, and mTOR and other signaling pathways. These provide potential therapeutic target in prostate cancer treatment.
Cancer is one of the leading causes of mortality amongst world’s population, in which prostate cancer (PCa) is one of the most encountered malignancies among men. Several molecular mechanisms are involved in prostate cancer development and progression. These include common survival factors in prostate cancer (IGF-1), growth factors (TGF-α, EGF), Wnt, Hedgehog, NF-κB, and mTOR and other signaling pathways. These provide potential therapeutic target in prostate cancer treatment.
MCE offers a unique collection of 2295 compounds with identified and potential anti-prostate cancer activity. MCE Anti-Prostate Cancer Compound Library is a useful tool for anti-prostate cancer drugs screening and other related research.
MCE Anti-Prostate Cancer Compound Library can be supplied as pre-dissolved Solutions or Solid. For pre-dissolved solutions in this library, there are 2241 compounds supplied in 10 mM solution, 49 compounds supplied in 2 mM solution and 5 compounds supplied in 3 mg/mL solution.
For pre-dissolved solutions, 10 mM for compounds with the solubility not lower than 10 mM, 2 mM for compounds with solubility between 2 mM and 10 mM, and 3 mg/mL for compounds with unconfirmed molecular weight and solubility not lower than 3 mg/mL.
Advantages:
- A unique collection of 2295 compounds for high throughput screening (HTS) and high content screening (HCS).
- A useful tool for the discovery of anti-prostate cancer drugs.
- Target diverse, medicinally active and cell permeable.
- Bioactivity and safety confirmed by preclinical research and clinical trials. Some have been approved by FDA.
- More detailed compound information with structure, IC50, and other chemical & biological data.
- High purity and quality validated by NMR and LC/MS.
Formulation: A collection of 2295 anti-prostate cancer inhibitors supplied as pre-dissolved Solutions or SolidSolution:2241 compounds supplied in 10 mM solution,49 compounds supplied in 2 mM solution,5 compounds supplied in 3 mg/mL solution.
Layout: 96-well storage tube or 96-well plate: 1st and 12th column are left empty.384-well plate: the first two columns and the last two columns are left empty.Compounds with different concentrations or dissolved in different solvents will be put on separate plates.This way of layout may increase the number of plates because there could be three solvents and three concentrations. If you have other requirements, please let us know.
Container: 96- or 384-well Plate with Peelable Foil Seal; 96-well Format Sample Storage Tube With Screw Cap and Optional 2D Barcode
English
Deutsch
